Preclinical evidences of safety of a new synthetic adjuvant to formulate with the influenza human vaccine: absence of subchronic toxicity and mutagenicity-Reference-Cited by-同舟云学术

Preclinical evidences of safety of a new synthetic adjuvant to formulate with the influenza human vaccine: absence of subchronic toxicity and mutagenicity

Published:2019-01-02 Issue:1 Volume:41 Page:140-149
ISSN:0892-3973
Container-title:Immunopharmacology and Immunotoxicology
language:en
Short-container-title:Immunopharmacology and Immunotoxicology

Author:

Cervantes-Torres Jacquelynne¹,Gracia-Mora Isabel²,Segura-Velazquez René³,Montero-Montoya Regina¹,Espinosa-Aguirre Javier¹,E. Gonsebatt María¹,Camacho-Carranza Rafael¹⁴,Rivera-Huerta Marisol²,Sanchez-Bartez Francisco²,Tinoco-Méndez Mabel²,Ostrosky-Wegman Patricia¹,Fragoso Gladis¹,Sciutto Edda¹

Affiliation:

1. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, Mexico;

2. Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, Mexico;

3. Unidad de Investigación, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México Ciudad de México, Mexico;

4. Facultad de Ciencias, Universidad Nacional Autónoma de México, Ciudad de México, Mexico

Funder

CONACyT

Fundación Miguel Alemán

Programa de Investigación para el Desarrollo y la Optimización de Vacunas, Inmunomoduladores y Métodos Diagnósticos del Instituto de Investigaciones Biomédicas

UNAM

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/08923973.2019.1566359

Reference38 articles.

1. Overview of Vaccine Adjuvants: Introduction, History, and Current Status

2. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants

3. A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine

4. Towards Identification of the Mechanisms of Action of Parasite-Derived Peptide GK1 on the Immunogenicity of an Influenza Vaccine

5. Towards a Taenia solium Cysticercosis Vaccine: an Epitope Shared by Taenia crassiceps and Taenia solium Protects Mice against Experimental Cysticercosis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GK-1 Induces Oxidative Stress, Mitochondrial Dysfunction, Decreased Membrane Potential, and Impaired Autophagy Flux in a Mouse Model of Breast Cancer;Antioxidants;2022-12-27

2. Influence of adjuvants on the amount, specificity and functional activity of antibody response to human influenza vaccine in mice;Molecular Immunology;2021-07

3. GK1: An Alternative Treatment to Control the Respiratory Complications During COVID19;Archives of Medical Research;2021-04

4. Plant-made vaccines against parasites: bioinspired perspectives to fight against Chagas disease;Expert Review of Vaccines;2021-03-05

5. Helminth-derived peptide GK-1 induces Myd88-dependent pro-inflammatory signaling events in bone marrow-derived antigen-presenting cells;Molecular Immunology;2020-12